Overview

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
To determine the time-course of plasma and CSF concentrations of intravenous (IV) ondansetron in healthy subjects, with and without selective inhibition of Pgp efflux transporter.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Ondansetron